Abaloparatide is a lab-made analogue of PTHrP, a protein related to parathyroid hormone, and is the active ingredient in Tymlos.1,2 It is FDA-approved for postmenopausal women with osteoporosis at high risk of fracture, and to increase bone density in men with osteoporosis at high risk of fracture.1 In the label’s main trial of 1,645 postmenopausal women, new spine fractures over 18 months occurred in 0.6% of the abaloparatide group and 4.2% of the placebo group.1 The label states that abaloparatide caused a bone cancer called osteosarcoma in rats and that it is unknown whether it causes osteosarcoma in humans.1
Abaloparatide at a glance
What it is
A PTHrP(1-34) analogue that the label says acts on the PTH1 receptor and stimulates new bone formation.1
FDA status
FDA-approved. Drugs@FDA lists Tymlos with an original approval date of April 28, 2017. The cited label has no boxed warning; its warnings include a risk of osteosarcoma seen in rats.1,2
Human evidence
A large randomized, placebo-controlled fracture trial in postmenopausal women and a smaller randomized trial in men, both described in the label.1
Evidence strength
Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned
What is abaloparatide?
Abaloparatide is a lab-made peptide modelled on the first 34 amino acids of parathyroid hormone-related protein (PTHrP). The label describes it as a PTHrP(1-34) analogue.1
In the United States it is the active ingredient of Tymlos, according to Drugs@FDA.2
How does abaloparatide work?
The label states that abaloparatide activates the PTH1 receptor, which stimulates bone-building cells called osteoblasts and new bone formation.1
The label reports that in rats and monkeys it increased bone density and bone mineral content, which correlated with increased bone strength.1
What do human studies show?
The label describes an 18-month randomized, double-blind, placebo-controlled trial in 1,645 postmenopausal women with osteoporosis. New spine fractures occurred in 0.6% of the abaloparatide group and 4.2% of the placebo group, a relative risk reduction of 86%.1
Fractures outside the spine occurred in 2.7% of the abaloparatide group and 4.7% of the placebo group by the end of the treatment period, according to the label.1
In a 12-month randomized trial of 228 men with osteoporosis, the label reports increases in bone density. The label’s indication for men is to increase bone density, not to reduce fractures.1
The label states that the safety and effectiveness of abaloparatide have not been evaluated beyond 2 years of treatment.1
What the evidence base contains
Large randomized human trial Study 003 (NCT01343004): an 18-month randomized, double-blind, placebo-controlled trial in 1,645 participants, postmenopausal women aged 49 to 86 with osteoporosis, with new spine fractures as the main outcome.1
Controlled human trial Study 019 (NCT03512262): a 12-month randomized, double-blind, placebo-controlled trial in 228 men with osteoporosis that measured bone density.1
Yes. Drugs@FDA lists Tymlos, application NDA208743, with an original approval date of April 28, 2017.2
The Tymlos label cited here (DailyMed SPL version 19, published August 17, 2026) states that it is indicated for postmenopausal women with osteoporosis at high risk for fracture, or who have failed or cannot tolerate other osteoporosis therapy, and to increase bone density in men with osteoporosis at high risk for fracture.1
The label has no boxed warning. It states that abaloparatide is contraindicated in people with a history of severe allergic reactions to it, which have included anaphylaxis and angioedema.1
Its warnings cover allergic reactions, a risk of osteosarcoma based on rat studies, a fall in blood pressure on standing, high blood calcium, and high urine calcium with kidney stones.1
DailyMed publishes the Tymlos label version cited on this page.1
What is still unknown?
Whether abaloparatide causes osteosarcoma in humans, which the label says is unknown.1
Its effects beyond 2 years of treatment, which the label says have not been evaluated.1
Whether it reduces fractures in men: the label’s trial in men measured bone density.1
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Abaloparatide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Abaloparatide are the records PeptideScanner has selected and published, not every registration or paper about Abaloparatide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
FDA-approved as Tymlos for osteoporosis. A large randomized, placebo-controlled trial described in the label found fewer new spine fractures than placebo. The label states that abaloparatide caused osteosarcoma in rats and that it is unknown whether it does so in humans.↗↗
Review source snapshots checked September 14, 2026 · Integrity checked September 14, 2026.
Three selected primary reports in osteoporosis: ACTIVE, its ACTIVExtend follow-up, and ATOM. The extension follows participants from ACTIVE rather than providing an independent replication.↗↗↗
What the reviewed sources report
ACTIVE reported fewer new vertebral and nonvertebral fractures with abaloparatide than placebo in postmenopausal women. Its extension studied subsequent alendronate in both groups. ATOM reported greater bone-density gains in men; that endpoint does not by itself establish fracture reduction in men.↗↗↗
What remains unresolved?
How do fracture outcomes and harms compare with other treatments over longer follow-up and in populations outside these selected trials?↗↗↗
Does the bone-density improvement observed in ATOM translate into fewer fractures in men?↗
The cited label covers postmenopausal women with osteoporosis at high fracture risk or failure or intolerance of other available osteoporosis therapies. For men in the corresponding osteoporosis population, its indication is to increase bone density; that wording differs from the fracture-reduction account for women. Label: 1 ↗
Which safety limits matter?
The label contraindicates severe hypersensitivity, including reported anaphylaxis and angioedema. Warnings also address osteosarcoma risk, orthostatic hypotension, high blood calcium and urinary calcium or stones. The rodent osteosarcoma finding does not establish that Tymlos causes osteosarcoma in humans. Label: 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Label ZIP SHA-256: 0972d261dcba3ae48d54920e976a32e45e2f7b9f8c2f3458dd827ca900db9c44. Extracted XML SHA-256: 4ac5a2ba440d0e916a9741978deee40d0ba4d42f291d6e40d1d113dae70b533f.
Three selected primary reports in osteoporosis: ACTIVE, its ACTIVExtend follow-up, and ATOM. The extension follows participants from ACTIVE rather than providing an independent replication.123
Bottom line from this bounded source set
ACTIVE reported fewer new vertebral and nonvertebral fractures with abaloparatide than placebo in postmenopausal women. Its extension studied subsequent alendronate in both groups. ATOM reported greater bone-density gains in men; that endpoint does not by itself establish fracture reduction in men.123
Reviewed study record
ACTIVE: fracture outcomes in postmenopausal women
Design
An 18-month randomized Phase 3 trial compared blinded abaloparatide and placebo groups, with an additional open-label teriparatide group.1
Population
The trial enrolled 2,463 postmenopausal women with osteoporosis; 1,901 completed the study.1
Outcomes reported
The authors reported fewer new vertebral and nonvertebral fractures and greater bone-density gains with abaloparatide than placebo. Reported hypercalcemia occurred in 3.4% with abaloparatide and 6.4% with teriparatide.1
Limitations
Follow-up was limited to 18 months and the teriparatide comparison was open-label. These results do not establish outcomes in men or all osteoporosis populations. PubMed links a 2017 erratum to this report.1
Reviewed study record
ACTIVExtend: follow-up of ACTIVE participants
Design
An extension followed eligible ACTIVE completers, with both groups subsequently receiving alendronate. It did not randomly assign a new independent cohort.2
Population
The extension enrolled 558 women from the former abaloparatide group and 581 from the former placebo group.2
Outcomes reported
Across the integrated 43-month period, the authors reported new radiographic vertebral fractures in 0.9% of evaluable women in the abaloparatide/alendronate group versus 5.6% in the placebo/alendronate group.2
Limitations
The findings describe a treatment sequence among participants who entered the extension. They cannot isolate ongoing abaloparatide effects or establish outcomes after stopping all treatment.2
Reviewed study record
ATOM: bone-density outcomes in men
Design
A 12-month randomized placebo-controlled trial used change in lumbar-spine bone mineral density as its primary endpoint.3
Population
A total of 228 men with osteoporosis were randomized: 149 to abaloparatide and 79 to placebo.3
Outcomes reported
Reported lumbar-spine bone-density gains were 8.48% with abaloparatide versus 1.17% with placebo. Common reported adverse events included injection-site reactions and dizziness.3
Limitations
Bone density was the primary endpoint; the reported gains should not be presented as demonstrated fracture reduction. The sample and duration limit conclusions about uncommon or longer-term harms.3
No registered Crossref update in the reviewed snapshotChecked September 14, 2026 for DOI 10.1001/jama.2016.11136. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 14, 2026 for DOI 10.1210/jc.2018-00163. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 14, 2026 for DOI 10.1002/jbmr.4719. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
ATOM’s primary result concerns bone density in men
NCT03512262 enrolled 228 men and measured lumbar-spine bone mineral density at 12 months. The posted modeled mean changes are 8.4820% with abaloparatide and 1.1654% with placebo; this endpoint is distinct from a direct fracture-reduction estimate. NCT03512262 ↗
More findings and the sources behind them
Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.
Randomized and analyzed counts differ
ATOM randomized 149 participants to abaloparatide and 79 to placebo, while its primary outcome table lists 119 and 66 evaluable participants. The total randomized sample should not be presented as the number with an observed 12-month measurement. NCT03512262 ↗
The extension studies sequential treatment
NCT01657162 enrolled eligible completers from the earlier abaloparatide-versus-placebo trial and then used alendronate in both groups. It evaluates treatment sequences; it is not a new randomized comparison of continued abaloparatide against placebo. NCT01657162 ↗
The fracture window starts before the extension
The extension’s primary vertebral-fracture endpoint runs from the parent trial’s baseline to extension month six. Its counts therefore should not be described as new fractures arising only during the extension, or compared with another trial without matching the time window. NCT01657162 ↗
What remains to be checked
Reconcile ATOM missing-data methods and fracture outcomes with the primary report and regulatory supplement.
Appraise sequential-treatment follow-up without counting parent and extension participants twice.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Why do official accounts report different fracture results?
EMA’s 2022 assessment excluded two ACTIVE sites after good-clinical-practice findings, reducing the analysis population from 2,463 to 2,070. Vertebral-fracture benefit remained, but nonvertebral-fracture efficacy was not statistically established in that subset. The older FDA clinical review reported a nonvertebral-fracture reduction. These accounts use different analysis contexts; their estimates should not be pooled as independent trials. EMA PDF pp. 180, 181, 182 ↗FDA PDF pp. 17 ↗
More findings, study links and document coverage
What did EMA conclude, and what remained uncertain?
The 2022 CHMP assessment supported authorization for postmenopausal osteoporosis at increased fracture risk after considering the total evidence. It retained cardiovascular uncertainty in vulnerable patients and requested an EU safety study. The reviewed report does not establish today’s completion status of that study. EMA PDF pp. 188, 189, 190 ↗
Which studies overlap?
ACTIVE (BA058-05-003) and its extension BA058-05-005 are a study family. The extension followed prior participants receiving alendronate; it was not an independent replication of the original randomized trial. EMA PDF pp. 180, 181 ↗
Selected sections read in 2 of 10 inventoried documents; 7 not yet reviewed; 1 unavailable. Reading selected sections does not establish complete appraisal of a document.
English PDF entries containing Eladynos in the title in the retained September 15 EMA document-feed snapshot, plus selected FDA approval-package documents. Includes candidate associations, not a complete FDA inventory, national authorizations or worldwide coverage. Live EMA page requests returned HTTP 429 on September 16; fresh page reconciliation is pending. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
Resolved feed conflict: the PDF identifies EMEA/H/C/005928/0000 on page 1; the feed incorrectly associates this document with the older EMEA/H/C/004157 application. The older refusal remains separate.
Verified: Eladynos · EMEA/H/C/005928 · Document dated 2022-10-13. Identity checked on PDF pp. 1.
Identity and procedure history; benefit-risk discussion, evidence limitations and recommendations, pages 180–190. Other sections have not been appraised.
PDF retrieval through the web reader returned HTTP 429 on September 16 after a backoff. No payload or internal application identity was verified; the older application number in the feed remains unconfirmed for this document.
Feed-listed application (not a verified association): EMEA/H/C/004157.
Remaining work
Review the remaining EMA assessment, product-information, risk-management and change documents; reconcile historical applications separately.
Reconcile later FDA supplements and current postmarketing-study status. Earlier review conclusions are dated evidence, not a current approval-status substitute.
Complete full-text and correction appraisal of the related literature. Registry identity matching does not establish that all posted results or historical registry versions have been reviewed.
European medicine records · 2 products or applications
EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.
Active substance as listed: abaloparatide. EMA record ↗
Refusal: 2019-01-07. EMA metadata last updated 2019-02-14. EMA metadata ↗
Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
396 retrieved · 3 included · 0 excluded · 393 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Abaloparatide"[Title/Abstract] OR "Tymlos"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
The 2017 ACTIVE correction has been read and compared with selected review v1. Corrected figure data, the supplement and full statistical appraisal remain open; this is partial reconciliation.
Showing 25 of 396 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 36190391 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: abaloparatide-PMID36190391-registry-linkage-unresolved.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 29800372 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01657162.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 27533157 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01343004.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
The correction extends Figure 3C time-to-event markers that ended one month early and clarifies that the supplement eFigure 2 legend describes a geometric mean of ratios. The publisher says the article was corrected online. Read the correction ↗
Compared with the selected Human Evidence Review version 1: it does not reproduce Figure 3C or the eFigure 2 measurements. This check does not establish that every study result is unaffected.
Still unresolved: The corrected figure data, supplement and full statistical analysis still require independent reconciliation before a complete study appraisal.
Read 2026-09-15 · Correction: Incorrect Figures, January 24/31, 2017.
Notice XML SHA-256 8e3150fa3439f119ece5d2a11c75a73f5ed25e46359fbbf186928e3f95f570e1.
PubMed 42671953 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42652552 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42648994 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42618812 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42577358 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42535103 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42532988 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42503281 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42498818 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42494964 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42494861 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42464584 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42461643 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42420311 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42418005 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42351259 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42303774 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42298929 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42268882 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42181204 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42075559 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42033613 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
FDA NDA208743 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: ABALOPARATIDE.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
2 retrieved · 2 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EMEA/H/C/005928 — include: EMA feed product Eladynos; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/004157 — include: EMA feed product Eladynos; reported status: Refused. Exact indication and decision documents remain unappraised.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
10 retrieved · 7 included · 0 excluded · 3 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 10 of 10 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 43729 — include: Document linked by EMA product number; content unappraised. Eladynos : EPAR - Refusal public assessment report
EMA 57149 — include: Document linked by EMA product number; content unappraised. Eladynos : EPAR - Medicine overview
EMA 57153 — include: Document linked by EMA product number; content unappraised. Eladynos : EPAR - Public assessment report
EMA 57152 — include: Document linked by EMA product number; content unappraised. Eladynos : EPAR - All authorised presentations
EMA 58737 — include: Document linked by EMA product number; content unappraised. Eladynos : EPAR - Procedural steps taken and scientific information after authorisation
EMA 57150 — include: Document linked by EMA product number; content unappraised. Eladynos : EPAR - Risk-management-plan
EMA 57151 — include: Document linked by EMA product number; content unappraised. Eladynos: EPAR - Product information
EMA 16434 — not screened: Title-name match awaiting identity and document review. Public summary of the evaluation of a proposed product-specific
waiver: Abaloparatide for treatment of osteoporosis
EMA 21920 — not screened: Title-name match awaiting identity and document review. Questions and answers on refusal of the marketing authorisation for Eladynos (abaloparatide)
EMA 18806 — not screened: Title-name match awaiting identity and document review. P/0307/2014: EMA decision of 24 November 2014 on the granting of a product specific waiver for abaloparatide (EMEA-001667-PIP01-14)
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
26 retrieved · 0 included · 0 excluded · 26 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 26 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT03623633 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04663464 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03512262 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01343004 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00542425 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04760782 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04974723 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03708926 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07616401 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04167163 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04626141 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06154187 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03746041 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04366726 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06164795 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07587775 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06753864 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04064411 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01657162 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06898060 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04249232 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04936984 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03841058 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03710889 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04467983 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Abaloparatide?
FDA-approved as Tymlos for osteoporosis. A large randomized, placebo-controlled trial described in the label found fewer new spine fractures than placebo. The label states that abaloparatide caused osteosarcoma in rats and that it is unknown whether it does so in humans.↗↗
The cited status sources were checked through August 14, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Bibliography fields unavailable here for 24 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
1
FDA Federal Register documents
1
DailyMed SPL versions
16
Canonical profile
Published
Profile structured data
Published
Linked dated records
60
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsTrial–publication links · 3
These links come only from structured NCT and PMID identifiers declared by PubMed or ClinicalTrials.gov. They do not summarize the publications or establish findings.
We refreshed this profile's label citation to the reviewed SPL version 19, published 2026-08-17. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.
DailyMed lists Structured Product Labeling version 1 for the reviewed Abaloparatide label family with a published date of 2017-05-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Selected records span April 28, 2017 to August 17, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
DailyMed lists Structured Product Labeling version 19 for the reviewed Abaloparatide label family with a published date of 2026-08-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41812602 at 2026-08-10T10:49:08.791Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-03-11. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42351259 at 2026-08-10T18:13:52.323Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42498818 at 2026-08-10T18:13:56.743Z. PubMed recorded a metadata revision date of 2026-07-24 and an Entrez history date of 2026-07-24. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained ClinicalTrials.gov record NCT07587775 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was abaloparatide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41714054 at 2026-08-10T18:13:42.699Z. PubMed recorded a metadata revision date of 2026-07-08 and an Entrez history date of 2026-02-19. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 39789749 at 2026-08-10T18:13:36.068Z. PubMed recorded a metadata revision date of 2026-07-07 and an Entrez history date of 2025-01-10. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41579168 at 2026-07-30T16:11:44.866Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-01-24. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42033613 at 2026-07-30T16:14:16.695Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2026-04-25. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41023931 at 2026-07-30T16:14:12.886Z. PubMed recorded a metadata revision date of 2026-06-26 and an Entrez history date of 2025-09-30. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41506099 at 2026-07-30T16:14:13.082Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2026-01-08. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 40890141 at 2026-07-30T16:14:11.108Z. PubMed recorded a metadata revision date of 2026-06-19 and an Entrez history date of 2025-09-01. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.↗